Gamunex-C Lot Withdrawn

On Feb. 20, 2025, Grifols Therapeutics LLC withdrew one lot Gamunex-C^® (immune globulin injection [human], 10% caprylate/chromatography purified) 40G vial to the consumer level for due to an increased rate of reported hypersensitivity reactions with the affected lot. Gamunex-C is an immune globulin solution indicated for treating primary humoral immunodeficiency (PI) in patients two years of age or older, idiopathic thrombocytopenic purpura (ITP) in adults and children and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Hypersensitivity and anaphylactic reactions are listed in the warnings and precautions section for the prescribing information; however, this lot may pose a higher risk for these reactions. To read more about the recall see here.